How can you control the administration of calcimimetics for your patients with chronic kidney disease who are on hemodialysis and suffering from secondary hyperparathyroidism, also known as sHPT? John Russell, MD sits down with two community nephrology professionals, Adbul Abdellatif, MD, FASN from Houston, Texas, and Debbie Glidden, MSN, APRN-BC, CNN from Orlando, Florida. They will be discussing a dosing practice involving oral cinacalcet and what alternatives they suggest for nephrologists who are concerned about controlling the administration of sHPT treatment in an approved fashion.

This promotional, non-CME program is intended for US Health Care Professionals. Adbul Abdellatif, MD, FASN and Debbie Glidden, MSN, APRN-BC, CNN were paid a fee by Amgen for their participation in the program.

When your patients with chronic kidney disease who are on hemodialysis are suffering from secondary hyperparathyroidism, also known as sHPT, what can you do? John Russell, MD sits down with two community nephrology professionals, David Henner, DO from Pittsfield, Massachusetts, and Debbie Glidden, MSN, APRN-BC, CNN from Orlando, Florida, to discuss just that. Learn what these clinicians did to treat sHPT before Parsabiv®, and how the arrival of Parsabiv® changed things for them, their practices, and their patients.

This promotional, non-CME program is intended for US Health Care Professionals. David Henner, DO and Debbie Glidden, MSN, APRN-BC, CNN were paid a fee by Amgen for their participation in the program.

The benefits of high-sensitive troponin expands beyond the Emergency Department to Cardiology. When used in conjunction with clinical findings, high-sensitive troponins can enable earlier diagnosis of myocardial infarction, more confident dispositions, and improved patient satisfaction than conventional troponins.

Joining Dr Jennifer Caudle is Dr Lori Daniels, Director of the Cardiovascular Intensive Care Unit and the University of California in San Diego, who discusses the adoption of Elecsys Troponin T Gen 5 in her health system.

Providing healthcare practitioners with nearly 75 percent of the patient data needed to make a clinical decision, the laboratory can be a valuable partner in improving quality measures and evaluating novel biomarkers throughout a hospital or health system.

Joining Dr Jennifer Caudle is Dr Ibrahim Hashim, Professor and Chief of Clinical Pathology at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital in Dallas Texas, who discusses how the lab played a pivotal role in the adoption of Elecsys Troponin T Gen 5 at Parkland Memorial Hospital.

Although 6 million patients visit the Emergency Department every year with chest pain symptoms1, less than 4 percent of those visits lead to a diagnosis of acute myocardial infarction2.

To address this gap, Dr. Jennifer Caudle is joined by Dr. Christopher Baugh, Vice Chair of Clinical Affairs at Brigham and Women's Hospital and Associate Professor at Harvard Medical School in Boston Massachusetts, who discusses the adoption of Elecsys Troponin T Gen 5 across the system's Emergency Departments.

References

1. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics, https://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2013_ed_web_tables.pdf (accessed February 27, 2020).
2. Hsia, R.Y., Z. Hale and J.A. Tabas. (2016). A National Study of the Prevalence of Life-Threatening Diagnoses in Patients with Chest Pain. JAMA Internal Medicine 176(7):1029–1032.

Patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) may still be at risk for major cardiovascular (CV) events, despite taking medications consistent with guideline recommendations. Dr. Becker and Dr. Lee are here to share their perspectives on managing patients with chronic CAD/PAD who are at risk for CV events. They will also discuss the efficacy and safety results of the pivotal COMPASS trial and provide clinical guidance for deciding who should be considered for treatment with XARELTO® (rivaroxaban) 2.5 mg twice daily in combination with low-dose aspirin 75 mg to 100 mg once daily.

Biomarker testing is a critical step in any mNSCLC patient’s treatment journey, as PGA champion Jason Day found out when his mother, Dening, was diagnosed with the disease.1-3

In this video, Jason and Dening tell their story about how biomarker testing helped Dening get on a therapy that can target the driver of her disease. Jason and Dening’s story may help your newly diagnosed mNSCLC patients understand the importance of testing their lung cancer, knowing the full molecular results, and treating based on those results.

Share this video and more with your patients by visiting TestLungCancer.com.

References:

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
2. Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J …

Biomarker testing is a critical step in any mNSCLC patient’s treatment journey, as PGA champion Jason Day found out when his mother, Dening, was diagnosed with the disease.1-3

In this video, Jason and Dening tell their story about how biomarker testing helped Dening get on a therapy that can target the driver of her disease. Jason and Dening’s story may help your newly diagnosed mNSCLC patients understand the importance of testing their lung cancer, knowing the full molecular results, and treating based on those results.

Share this video and more with your patients by visiting TestLungCancer.com.

References:

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
2. Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J ...

The benefits of high-sensitive troponin expands beyond the Emergency Department to Cardiology. When used in conjunction with clinical findings, high-sensitive troponins can enable earlier diagnosis of myocardial infarction, more confident dispositions, and improved patient satisfaction than conventional troponins.

Joining Dr Jennifer Caudle is Dr Lori Daniels, Director of the Cardiovascular Intensive Care Unit and the University of California in San Diego, who discusses the adoption of Elecsys Troponin T Gen 5 in her health system.

Providing healthcare practitioners with nearly 75 percent of the patient data needed to make a clinical decision, the laboratory can be a valuable partner in improving quality measures and evaluating novel biomarkers throughout a hospital or health system.

Joining Dr Jennifer Caudle is Dr Ibrahim Hashim, Professor and Chief of Clinical Pathology at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital in Dallas Texas, who discusses how the lab played a pivotal role in the adoption of Elecsys Troponin T Gen 5 at Parkland Memorial Hospital.